A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
Status:
Recruiting
Trial end date:
2025-04-15
Target enrollment:
Participant gender:
Summary
This is a single-arm, open, multicenter II phase clinical study to compare the efficacy and
safety of HAIC combined with Apatinib and Camrelizumab in the treatment of unresectable
middle-advanced MTM-HCC.